| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.35 | 0.02 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.02 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | PF-4708671 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.02 |
| mRNA | itraconazole | CTRPv2 | pan-cancer | AAC | 0.09 | 0.02 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | -0.086 | 0.02 |
| mRNA | Cyclopamine | FIMM | pan-cancer | AAC | 0.33 | 0.02 |
| mRNA | EHT 1864 | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |